【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 What Is This Report About? 8
3 Definitions of Markets/Categories Covered 9
3.1 Drug Delivery Devices 9
3.1.1 Metered Dose Inhaler Devices 9
4 Company Snapshot 10
4.1 Key Facts 10
4.2 Company Overview 10
4.3 SWOT Snapshot 10
5 Business Description 11
5.1 Business Overview 11
5.2 Animal Health 11
5.2.1 Overview 11
5.2.2 Financials 11
5.2.3 Market View 11
5.3 Human Pharmaceuticals 12
5.3.1 Overview 12
5.3.2 Financials 12
5.3.3 Market View 12
5.4 Human Pharmaceuticals 12
5.4.1 Overview 12
5.4.2 Financials 12
5.4.3 Market View 12
5.5 Major Products and Services 13
5.5.1 Overview 13
6 History 15
7 Business Strategy 21
7.1 Mission Statement 21
8 SWOT Analysis 22
8.1 Overview 22
8.2 Boehringer Ingelheim GmbH Strengths 22
8.2.1 Delivering Value through Innovation 22
8.2.2 Geographical Diversity 23
8.2.3 Contract Manufacturing Capabilities 23
8.2.4 Broad Product Portfolio 23
8.3 Boehringer Ingelheim GmbH Weaknesses 24
8.3.1 Pradaxa Lawsuit 24
8.3.2 Product Recalls 24
8.4 Boehringer Ingelheim GmbH Opportunities 24
8.4.1 Strategic Alliances 24
8.4.2 Market Growth in Emerging Economies 24
8.4.3 Growing CRO Industry 25
8.5 Boehringer Ingelheim GmbH Threats 25
8.5.1 Increased Scrutiny on Imports 25
8.5.2 Stringent Government Regulations 25
8.5.3 Uncertain R&D Outcomes 25
8.5.4 Cost Containment Pressures 26
9 Competitors 27
10 Competitive Landscape 28
10.1 Drug Delivery Devices (Metered Dose Inhaler Devices), Global, Market Share (%), 2011 28
10.2 Boehringer Ingelheim GmbH, Market (Metered Dose Inhaler Devices), by Region, Market Share (2011) 29
10.3 Boehringer Ingelheim GmbH, Drug Delivery Devices (Metered Dose Inhaler Devices), by Country, Market Share (2011) 30
11 Key Employees 32
12 Key Employee Biographies 33
13 Company Statement 34
14 Locations And Subsidiaries 35
14.1 Head Office 35
14.2 Other Locations & Subsidiaries 35
15 Financial Deals Landscape 36
15.1 Boehringer Ingelheim GmbH, Deals Volume Summary, 2007 to YTD 2013 36
16 Boehringer Ingelheim GmbH Detailed Deal Summary 38
16.1 Partnerships 38
16.1.1 BioGenes Enters Into Co-Development Agreement With Boehringer Ingelheim 38
16.2 Equity Offering 39
16.2.1 Vectura Group Completes Private Placement Of $7.22 Million 39
16.2.2 Boehringer Ingelheim Completes Private Placement Of Bonds For $1,250.5 Million 40
17 Recent Developments 41
17.1 Strategy And Business Planning 41
17.1.1 Sep 17, 2012: Boehringer Ingelheim To ShutDown One API Plant In Petersburg, Virginia 41
17.1.2 Sep 10, 2012: Boehringer Ingelheim Implements Flexible Fully Disposable Up- And Downstream Manufacturing For Biopharmaceuticals 41
17.1.3 Jun 18, 2012: Boehringer Ingelheim Sets Up Distinctive Brand For Biopharmaceutical Contract Manufacturing Business 41
17.1.4 May 31, 2012: Boehringer Ingelheim Expands Development Capacities With New Technical Center 42
17.1.5 Mar 12, 2012: Boehringer Ingelheim Sets Up First Asian Veterinary Research & Development Center In Shanghai 42
17.1.6 Dec 14, 2011: Boehringer Ingelheim Significantly Expands Supply Center For China 43
17.1.7 Sep 26, 2011: Boehringer Ingelheim Expands Business With Biosimilars 44
17.1.8 Jun 20, 2011: Boehringer Ingelheim Expands New Service With New Fill And Finish Capabilities 44
17.1.9 Feb 15, 2011: Pfenex And Boehringer Ingelheim Sign Non-Exclusive Strategic Agreement For Use Of Pfenex Expression Technology 44
17.1.10 Nov 27, 2009: Boehringer Ingelheim, Vectura Terminate Collaboration 45
17.1.11 Nov 09, 2009: Evotec Extends Research Collaboration With Boehringer Ingelheim 45
17.1.12 Oct 22, 2009: Evotec Obtains E2.5m Milestone Payment From Boehringer Ingelheim 45
17.1.13 Jun 15, 2009: Boehringer Ingelheim, Vitae Collaborate For Development Of Beta-Secretase Inhibitors 46
17.1.14 May 29, 2009: Boehringer Ingelheim, DxS Sign Collaboration Agreement 46
17.1.15 Jun 17, 2008: Boehringer Ingelheim To Acquire Actimis Pharmaceuticals 46
17.1.16 Apr 19, 2006: Vectura Enters Agreement With Boehringer Ingelheim 47
17.2 Financial Announcements 48
17.2.1 Aug 14, 2012: Boehringer Ingelheim Achieves Growth In H1 2012 48
17.2.2 Apr 24, 2012: Boehringer Ingelheim Reports Net Sales Of €13.2 Billion In 2011 49
17.2.3 Aug 09, 2011: Boehringer Ingelheim Reports Net Sales Of €6.4 Billion For H1 2011 49
17.2.4 Jul 28, 2009: Boehringer Ingelheim Posts First Half Financial Results 50
17.2.5 Aug 07, 2008: Boehringer Reports 1H 2008 Results 51
17.2.6 Jul 26, 2007: Boehringer Declares H1 2007 Results 52
17.3 Research And Development 53
17.3.1 Sep 19, 2012: Ten Pharmaceutical Companies Unite To Accelerate Development Of New Medicines 53
17.3.2 Jul 09, 2012: Boehringer Ingelheim Establishes Translational Research Collaboration With Harvard University In Areas Of Unmet Medical Need 54
17.3.3 Feb 29, 2012: Boehringer Ingelheim Expands Capabilities In Biopharmaceutical Process Science 54
17.3.4 Feb 03, 2012: Boehringer Ingelheim, GWT And TU Dresden Sign Diabetes Research Collaboration 55
17.3.5 Jan 17, 2012: CompleGen Announces Successful Delivery Of XenoGene Technology To Boehringer Ingelheim Under Non-Exclusive Agreement 56
17.3.6 Jan 05, 2012: FORMA Therapeutics Announces Collaboration With Boehringer Ingelheim For Development Of New Oncology Drugs 56
17.3.7 Feb 16, 2011: Québec Consortium for Drug Discovery Launches New Explore Program To Drive Innovation 56
17.3.8 Nov 22, 2010: f-star And Boehringer Ingelheim Partner To Develop New Therapeutic Antibodies 57
17.3.9 Oct 26, 2010: Boehringer Ingelheim Partners With MacroGenics To Discover, Develop And Commercialize DART-Based Antibody Therapeutics 57
17.3.10 Aug 26, 2010: Boehringer Ingelheim Opens Center of Competence In Shanghai 58
17.4 Corporate Communications 59
17.4.1 Jun 26, 2008: Boehringer Ingelheim Announces Board Changes 59
17.5 Government and Public Interest 60
17.5.1 Sep 12, 2012: Common Application For HIV Patient Assistance Program Expedites Application Process For Lifesaving Drugs 60
17.5.2 Oct 23, 2009: EMEA Issues Positive Opinion For Micardis 61
17.5.3 Oct 14, 2009: Boehringer Ingelheim Receives Marketing Authorisation From European Commission For Mirapexin/Sifrol 61
17.5.4 Oct 07, 2009: Astellas, Boehringer Ingelheim Reach Settlement With Impax 62
17.6 Product News 62
17.6.1 Oct 01, 2012: Boehringer Ingelheim’s New Project Transfer Program Enables Fast Track To Launch For Biopharmaceuticals 62
17.7 Other Significant Developments 63
17.7.1 Oct 26, 2012: Boehringer Ingelheim To Invest €85m In Dortmund Facility To Double Respimat Production 63
17.7.2 Apr 25, 2012: Boehringer Ingelheim Standardizes All Prescription Medicine Commercial Teams Worldwide On Cloud-Based, Veeva CRM And iRep 63
17.7.3 Apr 20, 2012: Boehringer Ingelheim Launches GLORIA-AF Registry Program To Investigate Use Of Antithrombotic Therapy 64
17.7.4 Jan 26, 2012: Boehringer Ingelheim Launches Lean-to-Clinic Program For Fast Drug Product Supply 65
17.7.5 Oct 20, 2011: Patheon Signs Three Year $18m Development Agreement With Boehringer Ingelheim 65
18 Appendix 66
18.1 Research Methodology 67
18.2 Secondary Research 67
18.3 Primary Research 67
18.4 Models 68
18.5 Forecasts 68
18.6 Expert Panels 68
18.7 GlobalData Consulting 68
18.8 Currency Conversion 69
18.9 Contact Us 70
18.10 Disclaimer 70
【レポート販売概要】
■ タイトル:Boehringer Ingelheim GmbH:市場シェア分析■ 英文:Boehringer Ingelheim GmbH Market Share Analysis
■ 発行日:2013年1月31日
■ 調査会社:GlobalData
■ 商品コード:GDATA403160221
■ 調査対象地域:グローバル
- Stomatitis (Sore Mouth):グローバル臨床試験レビューH2, 2013Stomatitis (Sore Mouth) Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Stomatitis (Sore Mouth) Global Clinical Trials Review, H2, 2013" provides data on the Stomatitis (Sore Mouth) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Stomatitis (Sore Mouth). It includes an overview of the trial numbers …
- 種子コーティング材料の世界市場:ポリマー、着色剤、ペレット、ミネラル/軽石、その他添加物The seed coating materials market is projected to grow at a CAGR of 7.6% from 2015 to reach a projected value of USD 1.63 Billion by 2020. The market growth is driven by increasing population demanding more food supply, rising technological advancement in the agricultural industry, and introduction of innovative seed technologies all over the globe, leading to increased use of seed coating materia …
- 風力タービン用ギアオイルの世界市場2016-2020About the Wind Turbine Gear Oil Market Wind power refers to the conversion of the kinetic energy of wind into electrical energy, which can be used by grids for distribution to end-users. Although known to users since prehistoric times, the use of wind energy as a mainstream power supply has been limited. Wind energy accounted for 0.21% of the global electricity net generation in 2000. In 2010, win …
- フローサイトメトリーの世界市場分析:技術別(セルベース、ビーズベース)、用途別(研究、産業、臨床)、エンドユーザー別(商業用、病院、学術、臨床研究)、製品・サービス別、セグメント予測、2014-2025The global flow cytometry market is expected to reach USD 8.0 billion by 2025, according to a new study by Grand View Research, Inc. The increasing incidence of infectious diseases and cancer is expected to upsurge the demand for flow cytometers for use in disease diagnosis over the coming years. In addition, higher number of physicians is inclined toward the usage of autologous and allogenic stem …
- 超小型LEDの世界市場予測(~2025年):LEDディスプレイパネル、LED照明機器The micro-LED market is estimated to be USD 254.1 Million in 2017 and is likely to reach USD 19,921.3 Million by 2025, at CAGR of 54.7% between 2019 and 2025. Increasing demand for brighter and more power efficient display panels for several applications is the main driver of the market. The market is also driven by factors such as increase in applications, high adoption rate of near-to-eye (NTE) …
- レーザー技術の世界市場予測(~2024年)“The laser technology market is expected to grow at a CAGR of 4.65% from 2018 to 2024”The overall laser technology market is expected to grow from USD 12.9 billion in 2018 to USD 16.9 billion by 2024, at a CAGR of 4.65%. Huge demand from the healthcare vertical, enhanced performance over traditional material processing techniques, and shift toward production of nano and micro devices are the key f …
- CNV-2197944(神経因性疼痛):医薬品市場予測及び分析(~2022)CNV-2197944 (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Althoug …
- 牧草用・飼料用機械の世界市場展望2017-2026According to Stratistics MRC, the Global Agricultural Haying & Forage Machinery Market is expected to grow at a CAGR of 5.27% during the forecast period. Factors such as rising demand for livestock population and increase in the concern of animal feed, growing demand for automation industry for the agricultural machinery equipment are expected to propel the market growth. However, low commodity pr …
- 魚及びシーフードの世界市場About Fish and Seafood Fish and seafood include various types of fishes and other eatable sea animals. The global population is growing, and with it, the demand for food, including seafood, is also increasing. According to the World Bank, it is expected that by 2030, 70 percent of the demand for fish and seafood will come from the APAC region. Therefore, to meet the demand for fish and seafood by …
- ホワイトバイオテクノロジーの世界市場分析:製品別(バイオ燃料、バイオマテリアル、生化学、工業用酵素)、用途別(バイオエネルギー、食品・飼料添加物、医薬品原料、パーソナルケア・家庭用品)、セグメント予測The global white biotechnology market is expected to reach USD 487.08 billion by 2024, according to a new report by Grand View Research, Inc. Rising awareness and emphasis for the adoption of greener and environment-friendly technologies in various end-use industries is expected to drive the market over the next eight years. Biofuels accounted for over 35% of the market in terms of revenue on acco …
- マイコプラズマ検査の世界市場2015The report presents a detailed analysis of the Mycoplasma diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Mycoplasma definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments: - Hospitals &n …
- Sherritt International Corporation:石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Sherritt International Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Sherritt International Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The rep …
- 航空機照明の世界市場予測(~2022年):室内照明、エクステリア照明The aircraft lighting market is projected to grow from an estimated USD 2.25 Billion in 2017 to USD 2.94 Billion by 2022, at a CAGR of 5.48% during the forecast period. This growth can be attributed to increasing aircraft orders due to the rise in passenger traffic across the globe. Also, increasing focus on safety compliance and passenger experience are factors influencing the growth of the aircr …
- Vasculitis:グローバル臨床試験レビューH1, 2013Vasculitis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Vasculitis Global Clinical Trials Review, H1, 2013" provides data on the Vasculitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vasculitis. It includes an overview of the trial numbers and their recruitment status as per the site of tri …
- バイオコハク酸の世界市場2019-2023About this market The increasing focus on the sustainable use of natural resources, the demand for bio-based or renewable chemicals is rising at a rapid rate. As bio-succinic acid is derived from natural resources, it is used as a replacement for building blocks such as adipic acid and phthalic anhydride, which are used to manufacture compounds such as polyols. The chemical composition of bio-succ …